Lineage tracing studies have become a well-suited approach to reveal cellular hierarchies and tumor heterogeneity. Cellular heterogeneity, particularly in breast cancer, is still one of the main concerns regarding tumor progression and resistance to anti-cancer therapies. Here, we review the current knowledge about lineage tracing analyses that have contributed to an improved comprehension of the complexity of mammary tumors, highlighting how targeting different mammary epithelial cells and tracing their progeny can be useful to explore the intra- and inter-heterogeneity observed in breast cancer. In addition, we examine the strategies used to identify the cell of origin in different breast cancer subtypes and summarize how cellular plasticity plays an important role during tumorigenesis. Finally, we evaluate the clinical implications of lineage tracing studies and the challenges remaining to address tumor heterogeneity in breast cancer.
Triple-negative breast cancer (TNBC) represents the most heterogeneous and aggressive subtype of breast carcinomas, characterized by the absence of clinical biomarkers (ERα, PR, and HER2) and the lack of targeted therapies. In this regard, several clinical trials have consistently failed to effectively stratify patients and identify specific treatments that elicit substantial responses. This study aims to pinpoint biomarkers expressed exclusively in the basal mammary epithelial compartment, facilitating a refined subclassification of this breast cancer subtype. Using computational analyses of single-cell RNA sequencing data, we have identified a list of genes associated with basal identity (BC-markers). Histological validation in 137 human samples has enabled us to categorize TNBC patients into BC-positive and BC-negative TNBC subtypes. Significantly, the presence of these markers correlates with a poorer prognosis in TNBC patients. Functional analyses have revealed a pivotal role for TAGLN in cell migration, likely influencing tumor aggressiveness. Further, we discovered that BC-marker expression is associated with the mesenchymal phenotype and increased sensitivity to the tyrosine kinase inhibitor dasatinib, particularly in BC-positive TNBC, suggesting novel therapeutic avenues. In our study, TAGLN emerged as a potential predictive biomarker for dasatinib responsiveness, offering new directions for personalized therapy for TNBC patients.
Triple-negative breast cancer (TNBC) is the most heterogeneous and aggressive subtype of breast carcinoma, characterized by the absence of clinical biomarkers and the lack of targeted therapies. Despite numerous clinical trials, patient stratification remains suboptimal, limiting the identification of effective treatment strategies. In this study, we aimed to identify biomarkers exclusively expressed in the basal mammary epithelial compartment to refine TNBC subclassification. Computational analysis of single-cell RNA sequencing data defined a set of basal identity genes, which were subsequently validated by immunohistochemistry in two independent TNBC cohorts. This approach enabled the identification of a TNBC subgroup, termed true basal TNBC (tB-TNBC), which was associated with poorer prognosis. High-throughput screening of 3,200 FDA-approved compounds in breast cancer cell lines classified according to basal marker expression identified dasatinib as a promising candidate with selective activity against tB-TNBC models. In tB-TNBC patient-derived xenograft models, dasatinib treatment effectively suppressed tumor growth. Furthermore, TAGLN emerged as a strong predictive biomarker of dasatinib response, with functional studies confirming its role in modulating drug sensitivity. Altogether, these findings support the clinical utility of basal markers for TNBC stratification and highlight a targeted treatment opportunity for patients with tB-TNBC. Significance: Basal biomarkers enable subclassification of triple-negative breast cancer and reveal a specific tumor subgroup sensitive to dasatinib, providing an effective stratification and treatment strategy for patients.
Identification of candidate compounds selectively targeting tB-TNBC cells. A, Heatmap showing the transcriptomic expression of tB-markers in a panel of breast cancer cell lines. B, Schematic representation of the FDA-approved drug library screening workflow. Cell viability heatmap shows the response of each cell line to the 3,200 tested compounds. ***, P < 0.001. C, Dot plot of average cell viability (%) in tB-TNBC (x-axis) and nB-TNBC (y-axis) cell lines after treatment. Dotted red and blue lines indicate the viability thresholds used for compound selection (20% in nB-TNBC). Colored dots highlight the selective compounds. D, Heatmap showing the viability percentages of the selected compounds across the four TNBC cell lines used in the screen. E, Correlation plots showing the association between ACTA2, TAGLN, and TPM2 expression (log2 TPM + 1) and dasatinib sensitivity (AUC) in breast cancer cell lines. Red lines, regression fit; shaded areas show 95% confidence intervals. P values calculated by Pearson correlation. B, Created in BioRender. Rodilla, V. (2026) https://BioRender.com/qpb7bux.
Identification of BaC identity markers expressed in the basal compartment of healthy human breast. A, Schematic representation of a mammary gland duct cross-section, showing BaCs (blue) and LCs cells (red). ERαpos and ERαneg statuses are indicated by nuclear color. B, Integrated UMAP plot showing epithelial cell clustering from three murine scRNA-seq datasets. Color coding differentiates between BaCs (blue), ERαpos LC (red), and ERαneg LCs (green). C, UMAP plots showing the signature score of the top 20 DEGs associated with each epithelial compartment. Signature scores are color-coded from low (gray) to high (blue). D, UMAP plots showing expression levels of the top 10 BaC-associated genes across the integrated human dataset. Color gradient indicates expression levels from low (blue) to high (red). E, Representative IHC staining of breast tissue consecutive serial sections showing proteins expression of candidate BaC-associated genes. Scale bar, 50 μm. Arrows in the APOE panel highlight expression restricted to stromal cells. A, Created in BioRender. Rodilla, V. (2026) https://BioRender.com/qpb7bux.